Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Summary

Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph nodes involved with cancer) III or Stage IV (without evidence of disease) will take tetrathiomolybdate (TM) pills for two years. The objectives of the study are to: * Assess the safety and tolerability of tetrathiomolybdate in patients with breast cancer at high risk of tumor recurrence. * Observe the disease-free survival of patients in this trial. * Conduct background scientific experiments on tumor tissue and blood of patients in this study

Timeline

Start

2003-12

Primary completion

2023-03-02

Completion

2023-03-02

Publications

• Ramchandani D, Berisa M, Tavarez DA, Li Z, Miele M, Bai Y, Lee SB, Ban Y, Dephoure N, Hendrickson RC, Cloonan SM, Gao D, Cross JR, Vahdat LT, Mittal V. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun. 2021 Dec 15;12(1):7311. doi: 10.1038/s41467-021-27559-z.

Drugs

Indications